PCV59 Cost-Effectiveness of Dabigatran Etexilate Versus Apirin Plus Clopidogrel Combination in Stroke Prevention in Atrial Fibrillation (SPAF): Russian Payer Perspective

Autor:	D Belousov, E.V. Afanasieva, Anastasia Ustyugova, Y.I. Ashikhmin, Y.B. Belousov, V.Y. Mareev
Rok vydání:	2012
Předmět:	medicine.medical_specialty Cost effectiveness business.industry Health Policy Perspective (graphical) Public Health Environmental and Occupational Health Atrial fibrillation medicine.disease Clopidogrel Dabigatran Internal medicine Stroke prevention Cardiology medicine Intensive care medicine business medicine.drug
Zdroj:	Value in Health. 15:A122
ISSN:	1098-3015
DOI:	10.1016/j.jval.2012.03.662
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bff47f411d8886ea27f28f39abcfb92b https://doi.org/10.1016/j.jval.2012.03.662 Zobrazit plný text záznamu Full Text from ScienceDirect